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Abstract
Background: Assessing asthma control using standardised questionnaires is recommended as good clinical
practice but there is little evidence validating their use within primary care. There is however, strong empirical
evidence to indicate that age, weight, gender, smoking, symptom pattern, medication use, health service resource
use, geographical location, deprivation, and organisational issues, are factors strongly associated with asthma
control. A good control measure is therefore one whose variation is most explained by these factors.
Method: Eight binary (Yes = poor control, No = good control) models of asthma control were constructed from a
large UK primary care dataset: the Royal College of Physicians 3-Questions (RCP-3Qs); the Jones Morbidity Index;
three composite measures; three single component models. Accounting for practice clustering of patients, we
investigated the effects of each model for assessing control. The binary models were assessed for goodness-of-fit
statistics using Pseudo R-squared and Akaikes Information Criteria (AIC), and for performance using Area Under the
Receiver Operator Characteristic (AUROC). In addition, an expanded RCP-3Q control scale (0-9) was derived and
assessed with linear modelling. The analysis identified which model was best explained by the independent
variables and thus could be considered a good model of control assessment.
Results: 1,205 practices provided information on 64,929 patients aged 13+ years. The RCP-3Q model provided the best
fit statistically, with a Pseudo R-squared of 18%, and an AUROC of 0.79. By contrast, the composite model based on the
GINA definition of controlled asthma had a higher AIC, an AUROC of 0.72, and only 10% variability explained. In addition,
although the Peak Expiratory Flow Rate (PEFR) model had the lowest AIC, it had an AUROC of 71% and only 6% of
variability explained. However, compared with the RCP-3Qs binary model, the linear RCP-3Q Total Score Model (Scale 0-9),
was found to be a more robust ‘tool’ for assessing asthma control with a lower AIC (28,6163) and an R-squared of 33%.
Conclusion: In the absence of a gold standard for assessing asthma control in primary care, the results indicate that the
RCP-3Qs is an effective control assessment tool but, for maximum effect, the expanded scoring model should be used.
Background
The ability to identify poor control is a pre-requisite for
improving asthma. To achieve the guideline standards
for asthma there is a necessity for primary health care
professionals to efficiently assess and monitor symptom
control. To do this they must utilise questions and tools
that are simple and brief to use, easy for the patient to
understand, and have a scoring system meaningful to
both practitioner and patient. Assessment of asthma
control using a standardised tool is now considered
good clinical practice [1,2]. There is, however, a lack of
empirical evidence on the best tool to use in the pri-
mary care setting [3].
The complexity and variability of asthma makes pre-
diction of treatment response difficult [4]. With such a
complex disease, no single parameter can accurately
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classify and assess control in all individuals [5]. To build
an accurate clinical picture, a range of criteria have to
be assessed based on a patient’s symptoms, sleep distur-
bance, use of rescue medication, daily activity limitation,
patient and health professional overall assessment, and
lung function. The concern is that patients, and indeed
health professionals, often have a different understand-
ing of the language used to describe control [6]. This
creates a dilemma for those trying to improve the
assessment and management of asthma.
In UK primary care, the tool most commonly used is
the Royal College of Physicians 3 Questions(RCP-3Qs)
[7]. Conceived as a practical clinical tool that ‘makes
sense to both clinician and patient’ and ‘improves stan-
dards of care’ [7,8], its use has yet to be fully validated.
Recently, Thomas et al. (2009) [9] indicated that when
using the recommended Asthma Control Questionnaire
(ACQ) threshold of 1.0 for ‘well controlled’ or ‘not well-
controlled’ asthma, an RCP-3Q score of 0 was a good
predictor of well controlled asthma but the study was
small and the authors conceded that it could not be
considered a validation study. There is also an argument
that using standardised tools to assess and record rele-
vant information may create a more physician-centred,
or template-directed, consultation [10-12].
The UK Quality Outcomes Framework(QOF) rewards
practices for use of screening questionnaires in other
chronic conditions but not for asthma, despite the avail-
ability of recommended measurement instruments.
Therefore, the absence of a gold standard screening tool
for asthma is a barrier to its inclusion as a QOF out-
come measure. This may in turn impact on the consis-
tency of asthma review appointments in the community.
This paper adds to the limited knowledge available on
asthma control screening tools by examining the appro-
priateness of a number of different models of asthma
control assessment by:
• Creating models of control from an existing UK
data set
• Using statistical modelling to identify the most
appropriate model for assessing control.
Methods
Currently there is no recommended gold standard for
assessing asthma control in primary care. Consequently,
there is no gold standard against which a measure of
asthma control can be assessed. There is, however,
strong empirical evidence to indicate those factors
which are strongly associated and predictive of asthma
control. These include: patient characteristics such as
age, weight, presence of symptoms and symptom pat-
tern, as well as factors related to healthcare resource use
and organisation and provision of care. As a result, we
would expect a good measure of control to be one
whose variation was most explained by these factors,
and a poor measure to be one which bears little relation
to them. Therefore, utilising an extensive UK database,
we used multiple regression techniques and statistical
tests to examine a variety of current measures (assessing
the derived models for fit and performance). We then
identified which of them (e.g. GINA, RCP 3 questions)
was best explained by the independent variables.
Recruitment and Data Collection
Between the beginning of January 2001 and the end of
December 2005, over 1200 practices from throughout
the UK participated in an electronic audit of asthma
management. This provided cross-sectional observa-
tional review data for more than 78,000 patients from 0
to 99 years of age. The windows-based audit software
was informed by the assessment recommendations of
the British Thoracic Society (BTS) Guidelines for the
management of Asthma and consisted of six data
screens. Practice and patient personal details were com-
pleted prior to the consultation. The remaining screens,
addressing symptoms, inhaler technique, use of self-
management plans, compliance, health resource use,
education, and therapeutic management, were com-
pleted during the consultation. The template acted as an
aide memoir for conducting a thorough guideline-based
asthma review. Based on previous audit experience
[13,14], practices were encouraged to ask their patients
about night-day-activity-related symptoms and medica-
tion use/compliance in the 4 weeks prior to the review;
to observe and record peak expiratory flow rate and
inhaler technique at the review; to record ownership
and use of a self management plan, need for emergency
medication, and health service resource use, since their
last review.
For the purpose of the original audit, practice clinical
systems were searched for patients > 4 years of age
receiving preventative asthma medication BTS treatment
step 2 within the previous 12 month period. Systems
were also searched for patients who were over-using
their b2-agonist medication (more than 6 prescriptions
for a short acting bronchodilator in the previous 12
months). Identified patients who met these inclusion cri-
teria were then invited to the practice for a routine
review of their asthma. The only exclusion criterion
from the study was a co-morbidity of Chronic Obstruc-
tive Airways Disease(COPD). The review process was
part of normal practice routine. Nurses were not
expected to run special sessions in order to undertake
the review but were instead required to fit it into their
daily work schedule. Those patients who accepted the
invitation for a review were asked for written consent
for their consultation data to be downloaded
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anonymously on a monthly basis to a central database at
the research centre. Practices signed up to a 12 month
audit service and over the course of the year were sent
quarterly reports comparing their asthma management
with current BTS guidelines. For the purpose of this
study data analysis was confined to the information
from the first review consultation. In addition, due to
the differences in guideline management of children
under 13 years of age to adults with asthma [1], only
data on patients ≥13 years of age were included in the
analysis.
Data Collection: Additional Data
Prior to analysis the quality of the data was reviewed.
Whilst many of the variables were collected as a result
of the routine asthma review some were added or
enhanced for the purpose of the study. New patient
variables were constructed from the existing data. This
was then merged with the practice data which had been
enlarged by the addition of information about the prac-
tice and its geographical area. The final dataset included
a Body Mass Index score for each patient and a depriva-
tion indicator for the local area ward in which each GP
practice was located [15]. To investigate effects of urban
or rural living on asthma control and management, a
binary categorisation of rural/urban, [< > 15 persons per
hectare (pph) [16]] was attributed to all practices in the
dataset. Also added were: Quality Outcome Frameworks
points for each practice; distance of the practice to the
nearest district general hospital; and the availability of a
respiratory specialist within that hospital. The variables
used for the multi-level modelling process are itemised
in Table 1.
Control Models
Figure 1 outlines the project process, the shaded area
representing the methods and results described in this
paper. The dependent binary outcome variable was poor
control of asthma. Guided by two systematic reviews of
the literature [17] eight binary (Yes = poor control, No
= good control) models of asthma control were con-
structed (Figure 2) from the large UK database. The lit-
erature reviews were conducted according to strict
methodological criteria (Figures 3 &4) [18], and were
designed to define ‘poor’ asthma control; and to identify
the tools used in primary care to assess asthma control.
The reviews identified a total of 26 asthma control
assessment tools being used internationally in primary
care. However, the range of control models constructed
and analysed for this study were restricted by two
things:
• The complexity of the scoring mechanism in some
of the tools e.g. the Asthma Control Test (ACT) and
the Asthma Control Questionnaire (ACQ), made it
impossible to model the asthma data to suit the
score point for good and poor control.
• Many of the tools were based on the international
criteria for good and poor control [2] thus reducing
the necessity to model all the individual tools.
Thus, using the information from the literature
reviews, the data were modelled to mirror two of the
tools recommended by BTS/SIGN guidelines, the RCP-
3Qs (Figure 5) and Jones Morbidity Index (JMI) (Figure
6), and three composite measures, one based on the
Table 1 Variables used for regression modelling.
Patient Variables
Age Rescue use inhaled steroid***
Gender Rescue oral steroid***
Body Mass Index Emergency Nebulisation***
Active Smoker Scheduled Consult***
PEFR < 80% predicted/best* Unscheduled Consult***
Symptoms** Telephone Consult***
Days Off due to asthma** Home Visit***
Regularly forget preventer* Outpatient Visit***
Poor inhaler technique* A&E visit***
No Self management plan Admission to Hospital***
Overuse Short Acting
Bronchodilator**
Asthma Symptoms** Night/Day/
Activity
BTS Treatment Step
Practice Variables
Strategic Health Authority (SHA) Number GPs in practice
SHA Deprivation Full time (FT) Nurse in Practice
SHA Population Number of FT Nurses
Primary Care Trust (PCT) Part time (PT) Nurse in Practice
PCT Deprivation Number of PT Nurses
PCT Population Number of Nurses in practice
Ward Deprivation Way Asthma Care Provided
Ward Population Presence of Nurse Clinic
Rurality Nurse with Diploma Level Asthma
Training
Practice Previous Asthma Audit
Practice Population Previous use of Review Protocol
Full Time (FT) GP in Practice Asthma UK QOF Points
Number FT GPs Total UK QOF Points
Part time (PT) GP in Practice Distance nearest District General
Hospital
Number PT GPs Respiratory Consultant at DGH
* Assessed at the review consultation
**In the 4 weeks prior to the review consultation
*** Since previous review
Note: Variables used in the construction of a control dependent variable were
not used as an independent variable in the regression analysis for that particular
control model
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Global Initiative for Asthma(GINA) criteria [2] for con-
trolled asthma, one on the GOAL study [19] criteria for
total control, and another on the GOAL study [19] cri-
teria for well/moderately controlled asthma. The GOAL
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Shaded areas indicate elements of the study reported in this paper. 
Practices recruited to Audit Service 
n=1205 
Informed by the Reviews 
7 ‘Models’ of Control 
Constructed from Data 
Papers reviewed for reference to 
‘Asthma Control’ & ‘Measures 
of Control’. 
Systematic Reviews of the Literature 
 
Patients aged 13+ years  
n=64,929 
Descriptive Analysis of Data 
Study 2 
 
22 Papers 
 
Assessment ‘Tool’ 
Use 
Study 1 
 
16 Papers 
 
Defining Asthma 
Control 
Data Modelling 
Multiple Logistic & 
Linear Regression 
Analysis 
Figure 1 Flow of the study.
Systematic Review based Control Tool Study Interpretation of Control Model 
Specific Tool Control Assessment 
1 - RCP 3 Questions  
Poor Control = A positive answer to any 
question. 
 
 
Good Control = No to all questions 
Poor Control = A positive answer to any 
question i.e. either day or night symptoms, or 
activity limitation. 
 
Good Control = No day or night symptoms and 
no activity limitation 
2 - Jones Morbidity Index  
Low = 0 Yes answers 
Medium = 1 Yes answer 
High = 2-3 Yes answers 
Poor Control = ‘Yes’ answer to any question 
i.e. night symptoms; symptom frequency; days 
off due to asthma. 
 
Good Control = No ‘Yes’ to any question 
Composite Control Assessment  
3 - Controlled - GINA  
Daytime symptoms – ≤ 2 per week 
Nocturnal symptoms - None 
Activity limitation – None 
Reliever medication – Twice or less per week 
 
PEFR – Normal 
Daytime symptoms = ≤ 2 APRS score 
Night-time symptoms = 0 APRS score 
Activity limitation = 0 APRS score 
Reliever medication = <1-2 per week  
All above in previous 4 weeks 
PEF ≥80% predicted on day of review. 
4 – Moderately Controlled - GOAL study   
Daytime symptoms – 2-6 days/month 
Nocturnal symptoms - 3-4 nights/month 
Activity limitation – None 
Reliever medication – Minimal 
Days Off - None 
 
PEFR – Normal 
Daytime symptoms = ≤ 2 APRS score 
Night-time symptoms = ≤1 APRS score 
Activity limitation = 0 APRS score 
Reliever medication = <1-2 per week  
Days Off = 0 
All above in previous 4 weeks 
PEF ≥80% predicted on day of review.  
5 - Totally Controlled - GOAL study   
Daytime symptoms – None/Minimal  
Night-time symptoms - None 
Activity limitation – None 
Reliever medication – None/Minimal  
Days Off - None 
 
PEFR – Normal 
Daytime symptoms = 0 APRS score 
Night-time symptoms = 0 APRS score 
Activity limitation = 0 APRS score 
Reliever medication = <1-2 per week  
Days Off = 0 
All above in previous 4 weeks 
PEF ≥80% predicted on day of review.  
Single Item Control Assessment 
6 - Overuse of Short Acting Bronchodilator 
(SAB) 
Poor Control = ≥ twice a day 
Good Control = = ≤ once a day 
7 - Peak Expiratory Flow Rate (PEFR) Poor Control = <80% predicted/best 
Good Control = ≥80% predicted/best 
8 - Severity by British Thoracic Society (BTS) 
treatment step 
Severe = Steps 3, 4 or 5 
Not Severe = Steps 0, 1 or 2 
Figure 2 Asthma control assessment models constructed from
the data.
Types of Study  – Any of the following 
Review 1 & 2 
? Randomised Controlled Trials 
? Controlled trials 
? Quasi-randomised trials 
? Non-randomised trials 
? Observational studies 
? Systematic Reviews 
? Meta-analysis 
? Qualitative Studies 
Types of Participant – All of the criteria must be met 
Review 1 Review 2 
? People >4 years of age with a 
diagnosis  of asthma of any severity 
? Health professionals in any setting 
? People >4 years of age with a 
diagnosis of asthma of any severity 
being managed in primary care. 
? Primary care based health 
professionals caring for people with 
asthma. 
Types of Intervention – All of the criteria must be met 
Review 1 Review 2 
? Specifically defined asthma control. 
? Took place in any setting, 
healthcare or otherwise. 
? Discussed/compared results with 
usual practice or compared two (or 
more) interventions. 
? Specifically defined the tool used for 
monitoring asthma control 
? Utilised the monitoring tool within 
the review process. 
? Took place in a primary care/general 
practice setting. 
? Compared results with usual practice 
or compared two or more 
interventions. 
Types of Outcome – All of the criteria must be met 
A priori identified outcomes or process measures of included studies 
Review 1 Review 2 
? Specifically quantified a definition 
of asthma control 
? Described how the control 
definition was achieved 
? Specified use of a tool for monitoring 
and managing asthma control 
? Reported level of control 
? Described how the tool was utilised 
in monitoring asthma control 
Figure 3 Inclusion criteria for studies in the systematic review.
Types of Study 
Review 1 Review 2 
? Studies which focused on 
respiratory conditions other than 
asthma. 
? Studies which combined asthma 
with other respiratory conditions 
but did not report asthma results 
separately. 
? Control as a concept not defined, 
explained or discussed. 
? Studies which focused on drug 
trials or were economic studies. 
? Studies which focused on respiratory 
conditions other than asthma. 
? Studies which combined asthma with 
other respiratory conditions but did 
not report asthma results separately. 
? Control assessment as a concept not 
defined, explained or discussed 
? Studies which focused on drug trials 
or were economic studies. 
Types of Participant 
Review 1 & 2 
? Those with a respiratory condition other than asthma. 
Types of Intervention 
Review 1 Review 2 
? Interventions which did not define 
asthma control. 
? Interventions not related to the 
regular review and monitoring of 
symptoms and using a defined 
control assessment tool in a primary 
care setting. 
Types of Outcome 
Review 1 Review 2 
? None given that relate to control 
definition. 
? None given that relate to control 
measurement 
Note: For the purpose of Study 2, a control assessment tool is that which has been 
designed to assess level of asthma control and is a written/electronic record of patient 
response to a number of questions 
Figure 4 Exclusion criteria for studies in the systematic review.
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study criteria were based on the GINA definition of
asthma control.
Three single component models were also analysed
to assess their ability to predict poor control. Peak
Expiratory Flow Rate (PEFR) and overuse of broncho-
dilator medication are important components of a
composite assessment tool but have limited ability
when used in isolation [3]. This was tested within the
analysis. A severity model, based on BTS/SIGN treat-
ment step (Figure 7), was also investigated. Variables
used in the construction of each dependent outcome
were not used as independent variables in the regres-
sion analysis for that particular control model. Based
on the findings from the logistic regression, linear
regression was also carried out on an expanded score
model of the RCP-3 Questions (Figure 5). Scored by
question and frequency of symptoms [0(no symptoms)
to 3(daily symptoms)], each patient was allocated a
score between 0 and 9.
Royal College of Physicians 3 Questions for Asthma  
No to all questions consistent with controlled asthma 
In the last month YES NO 
 
“Have you had difficulty sleeping because of your asthma 
symptoms (including cough)?” 
 
“Have you had your usual asthma symptoms during the day 
(cough, wheeze, chest tightness or breathlessness)?” 
 
“Has your asthma interfered with your usual activities 
(e.g. housework, work, school, etc)?” 
 
  
 
Expanded Score for RCP-3Q’s 
Each question scored by frequency of symptoms  
0 = no symptoms 
1 = once or twice per month 
2 = once or twice per week 
3 = daily symptoms  
Allocated score between 0 and 9   
Figure 5 Royal College of Physicians 3 Questions for Asthma.
The Jones Morbidity Index  
No to all questions consistent with controlled asthma 
 During the past four weeks: 
1 Have you been in a wheezy or asthmatic condition at least once a week? 
2 Have you had time off work or school because of your asthma? 
3 Have you suffered from attacks of wheezing during the night? 
0 or 1 Yes Answer 2 Yes Answer 3 Yes Answer 
Low Morbidity Medium Morbidity High Morbidity 
Figure 6 Jones Morbidity Index.
BTS Treatment Steps – adults (13+ years)
Inhaled short acting bronchodilators as required
Step 1
Add inhaled steroids 200-800mcg per day
Step 2
1.  Add inhaled long acting bronchodilator (LABA)
2.  No response  - stop LABA & increase inhaled steroids to 800mcg per day
Consider Leukotrienes (LRTAs) or SR Theophyllines 
Step 3
Consider trials of increased inhaled steroids up to 2000mcg per day.
Addition of 4th drug – LTRA/SR Theophylline/Oral Beta
Step 4
Use daily steroids.
Maintain high doses of steroids 2000mcgs per day
Step 5
Figure 7 British Thoracic Society/SIGN Treatment Steps for
Asthma (13+ years).
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Statistical Analysis
Utilising the UK database descriptive statistics using
Chi-squared tests for categorical data and t-tests for
continuous data were carried out on the baseline data
using SPSSv15(SPSS Inc., 2006). The Chi-squared statis-
tic was reported for comparisons of categorical data and
the Chi-Squared test for trend reported where
significant.
Multiple regression modelling, accounting for practice
clustering of patients, was undertaken to determine the
strength of association of the independent variables
(Table 1) within each model. Multiple logistic regression
multi-level modelling was used to derive the eight sim-
ple binary (yes/no) models using STATAv9(Stata Corp
LP, 2007). Linear regression analysis was used to analyse
the RCP-3Q expanded score model. Model fit for all
logistic regression models was assessed using three
tests-Area Under the Receiver Operating Characteristic
(AUROC) (c-statistic) which measured the ability of the
model to predict control; Pseudo R-squared which was
used to assess the amount of explained variance within
the model; and Akaikes Information Criteria (AIC) used
to assess fit and performance. The linear regression
model was assessed using R-squared and AIC. Using
these measures we ranked the performance of all eight
models.
Ethical Approval
Ethical approval for the data collection was given by the
Regional Medical Research Ethics Committee.
Results
From the 10,432 primary care practices in the UK (cor-
rect at time of data collection), 1,205 practices of all
sizes and with a wide geographical spread, submitted
usable practice data and data on 64,929 patients who
attended for a routine asthma review. The study prac-
tices represented almost 12% of all UK practices. The
proportion of practices from England, Scotland and
Wales was similar (Table 2). Northern Ireland was con-
siderably lower.
Study practices were spread over all 28 English Strate-
gic Health Authorities (SHA); 11(73%) of the 15 Scottish
Health Boards; 16(73%) of the 22 Health Authorities in
Wales; and all four in authorities in Northern Ireland
(Figure 8). Practices were situated in 305(89%) of the
344 UK Primary Care Trusts (or equivalent e.g. Com-
munity Health Partnership (CHP) in Scotland).
The PCTs represented in the study had a higher mean
population size than the average for all UK PCTs [Study
Mean 220,940 (Upper Quartile(UQ) 247,996; Lower
Quartile(LQ) 130,180) v National Mean 170,872(UQ
207,796; LQ 112,355)], indicating a slightly higher num-
ber of urban or semi urban practices in the study
cohort. However, over 30% of the practices were situ-
ated in rural or semi-rural areas (Table 3).
Comparison of the mean local area deprivation score
[15] for the study cohort [Mean 1.6508 (UQ 3.8750; LQ
-1.1900)] with that for all UK practice wards [Mean
0.0009 (UQ 2.0848; LQ -2.6114)] confirmed that the
study cohort was skewed slightly towards practices in
more deprived areas, probably because of the higher
number of urban practices in the study.
Practice size ranged from very small (367) to very
large (32,000) (Table 3). Eight hundred and forty one
(70%) of the practices had an asthma register of between
5 and 10% of their total patient population.
Table 2 Participating practices by UK country
Total UK Practices Study Practices Proportion
England 8,551 1,014 11.9%
Scotland 1,014 116 11.4%
Wales 502 55 11.0%
Northern Ireland 365 20 5.5%
UK Total 10,432 1,205 11.6% Figure 8 UK distribution of study practices.
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Patient characteristics and asthma control status are
summarised in Table 4. The mean Body Mass Index
(BMI) of the study population was 26.16 (SD 5.79).
Thirty nine percent of patients (25,537) were within
normal BMI range (18 to 25). Nearly 54% were over-
weight or obese: 33% (21,546) were overweight (BMI 25
to 30); 21% (13,373) obese (BMI > 30). The proportion
of current smokers [13,531(21%)] was slightly lower
than the UK rate of approximately 1 in 4 adults [20].
At the time of the review 54,503 (83.9%) patients
reported experiencing some degree of asthma related
symptoms in the immediate 4 week period preceding
the consultation: 13,438 (20.7%) on one or two days in
the month; 17,451 (26.9%) patients one or two days a
week; and 23,614 (36.4%) on a daily basis. Four out of
five patients [52,178 (80%)] were on preventative asthma
medication (BTS treatment steps 2-5) prior to the
review. Although, as one would expect, level of treat-
ment step was significantly associated to symptom
reporting (Table 5), patients on all levels of treatment
were experiencing frequent symptoms (Figure 9).
Prior to the review 30,360(47%) patients were report-
edly overusing their reliever inhaler (more than 6 pre-
scriptions for a short acting bronchodilator in the
previous 12 months), with males statistically more likely
than females to be using it more than once every day
[M 12,938(48%) v F 17,422(46%); p < 0.0001 (OR 0.93
(95%CI 0.91-0. 96)]. Overuse increased with age, rising
from 2,361(33.5%) of patients in the 13 to 19 year age
band to 4,777(51%) of patients in the 70+ age range (p
< 0.0001). It was also associated with weight being
greatest in those with a BMI over 30 [6671(50%) of
13,373 patients] and lowest in those with a BMI of 18
to 25 [11,521(45%) of 25,537 patients] (p < 0.0001).
Reported overuse of inhaled reliever medication was
also linked to level of preventive medication treatment
step with patients on low or no preventative medication
more likely to overuse [Steps 0-2: 19,446(46%) v Steps
3-5: 10,914(36%); p < 0.0001 (OR 0.90(0.88-0.93)].
There was also a significant difference in the level of
poor compliance between:
• Gender-males being more likely than females to
forget their inhaler [M 8,672(32%) v F 10,197(27%);
p < 0.0001 (OR 1.27(1.23-1.32)].
• Medication treatment step-patients on treatment
step 0, 1 or 2 being more likely to forget to take
their inhaler than patients on steps 3, 4 or 5 [Steps
Table 3 Practice Baseline Characteristics (n = 1205)
Missing
Rurality: Urban practices 826 (68.5%) 0 (0.0%)
Practice population size Mean 6,862 5 (0.4%)
Lower Quartile 3,877.5
Upper Quartile 9,000
Range 367 to 32,000
Median 6,300
Practices with a: Full time GP 1,090 (90.5%) 91 (7.5%)
Part time GP 381 (31.6%) 91 (7.5%)
Full time nurse 787 (65.3%) 105 (8.7%)
Part time nurse 478 (39.6%) 105 (8.7%)
Deprivation Score Mean 1.65 (SD 3.62) 1 (0.08%)
Range -5.21 to 13.21
Median = 1.18
Distance of practice from the nearest DGH Mean 4.86 miles (SD 5.71) 1 (0.08%)
Range 0 to 96
Median = 3
Respiratory Specialist in-situ in nearest DGH 1,150 (95%) 35 (2.9%)
Practices who had:
Nurse run asthma clinic 830 (68.9%) 68 (5.6%)
Nurse with an accredited Asthma Diploma 897 (74.4%) 48 (4.0%)
Carried out asthma audit in the previous 3 years 723 (60.0%) 55 (4.6%)
Previous use of Asthma Stamp (Protocol) 561 (46.6%) 91 (7.5%)
Achieved ≥70% of Asthma QOF* Points 2004/5 617 (51.2%) 22 (1.8%)
Achieved ≥70% of Total QOF* Points 2004/5 1,152 (95.6%) 19 (1.6%)
QOF = Quality Outcome Framework
DGH = District General Hospital
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0-2: 14,495(34%) v Steps 3-5: 4,374(19%); p < 0.0001
(OR 2.16(2.08-2.25)].
• Age-teenagers and young adults being more likely
to forget to take their preventer inhaler [13-19 yrs:
2,890(41%); 20-29 yrs: 2,905(40%); 30-39 yrs: 4,029
(38), 40-49 yrs: 3,271(33%), 50-59 yrs: 2,426(24%),
60-69 yrs: 1,888(18%); and patients aged 70+yrs:
1,460 (15.5%) (p < 0.0001)].
• BMI-the more overweight a patient the less likely
they were to forget their preventer inhaler (BMI <
18: 1,501(34%); 18- < 25: 7,606(30%); 25-30: 6,108
(28%); 30+: 3,654(27%), (p < 0.0001).
Regression analysis of Asthma Control Models
Of the eight binary control models investigated, the
RCP-3 Questions provided the best fit statistically. It
had the second lowest AIC, highest pseudo R-squared
(amount of explained variability) of 18% and an AUROC
of 0.79 (Table 6). An AUROC of 0.79 is on a par with,
for example, the Framingham predictors of Coronary
Heart Disease [21]. By contrast, the composite model
based on the GINA definition of controlled asthma had
a higher AIC, an AUROC of 0.72, and only 10% variabil-
ity explained. The PEFR model had the lowest AIC, an
AUROC of 71% and only 6% of variability explained.
The Royal College of Physicians 3 Question model
was interrogated further to investigate whether expan-
sion to include a score for the various symptom fre-
quency levels within each of the three questions
contributed to a more robust assessment tool. Com-
pared with the RCP-3Q binary model the RCP-3Q
expanded score model provided the best fit with a lower
AIC (28,6163) and an R-squared of 33% (Table 6).
Discussion
Statistical modelling found the Royal College of Physi-
cians 3 Questions for asthma was the ‘best fit’ of the
control models tested for determining asthma control in
a routine review consultation. However, to be effective,
a simple scoring system should be incorporated into the
assessment process. The results may prove useful when
determining future support strategies for UK Primary
Care.
Strength of the Study
The difficulties observed in conducting randomised con-
trol trials in primary care means that the results from
good quality observational data need to be used for
planning and developing health care policy. Producing a
Table 4 Baseline characteristics for patients aged 13
years and over (n = 64,929)
Issues assessed/discussed at consultation Number %
Age Mean (SD) 46.9 (SD 19.5)
Patient numbers by age band: 13-19 years 7,047 11
20-29 years 7,258 11
30-39 years 10,616 16
40-49 years 10,029 15
50-59 years 10,298 16
60-69 years 10,259 16
70+ years 9,422 15
Female 37,826 58
Body Mass Index (BMI) Mean (SD) 26.16 (SD 5.79)
Patient numbers by BMI band: ≤18 4,473 7
> 18-25 25,537 39
> 25-30 21,546 33
> 30 13,373 21
PEFR at consultation < 80% predicted 1,971 3
Days off in last 4 weeks due to asthma 8,382 13
Smoker 13,531 21
Symptoms in last 4 weeks 54,503 84
Inhaler Device(s) Technique observed as poor 6,789 10
Inhaler occasionally forgotten/not taken 18,869 29
Self management plan not in use prior to
consultation
39,938 62
Temporary Increase in Inhaled Steroid since last
review
3,157 5
Rescue Oral Steroid since last review 3,223 5
Emergency Nebulisation since last review 1,528 2
Over use of Inhaled Short Acting Bronchodilator* 30,360 47
Scheduled consult since last review 2,626 4
Unscheduled consult since last review 1,755 3
Telephone consult since last review 321 0.5
Home visit since last review 158 0.2
Outpatient visit since last review 95 0.1
A&E visit since last review 292 0.4
Admission to Hospital since last review 58 0.1
BTS Treatment Step prior to review: BTS Step 0 5,477 8
BTS Step 1 7,274 11
BTS Step 2 29,629 46
BTS Step 3 10,678 16
BTS Step 4 11,491 18
BTS Step 5 380 1
*Overuse of Short Acting Bronchodilator = SAB inhaler required more than once
every day in the four weeks prior to the consultation
BTS = British Thoracic Society
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predictive model requires data representative of the gen-
eral asthma population. The practices that provided data
mirrored the distribution pattern of practices through-
out the UK and thus were representative of-urban,
semi-urban, semi-rural and rural area practices. They
ranged in size and represented a wide range of social
deprivation from highly deprived to highly affluent.
With all levels of deprivation strongly represented the
presence of slightly more deprived practice ward areas
in the dataset was in actual fact a strength of the study
as it ensured that any representation was in favour of
those areas where there is potentially poorer control of
asthma. This is preferable to over-representation of
more affluent areas where control may be better [22,23].
The patients were representative of genders, all ages,
and the full range of asthma severity. The number of
patients on individual practice asthma registers was con-
sistent with nationally expected numbers of asthmatic
sufferers within a practice [24]. The greater number of
women (F 58% v M 42%) in the study cohort is indica-
tive of both the higher rate of asthma in adult females,
particularly in the older age groups [25], and the ten-
dency for women to be more likely to attend for a
review [26]. The proportion of current smokers within
the dataset was only slightly lower than the UK smoking
rate and was most likely due to the fact that the patients
in the study were all suffering from a respiratory disease.
The decision to create a categorical variable was a
direct reflection of the structure of many of the control
assessment tools in use. Although control is on a conti-
nuum from mild to very severe it is apparent that a
desired feature from a clinical viewpoint should be a
distinct point at which poor control is considered a pos-
sibility. It should be emphasised that the assessment
questionnaires are not meant to be used as stand-alone
tools, but act as a guide to a more thorough review.
The data was from a very large representative cross
section of the UK’s primary care asthma community. In
addition, the regression techniques and goodness-of-fit
measures used to test the data ensured that the results
could be considered at least internally valid. The use of
AUROC, AIC, Pseudo R-squared, and R-squared,
allowed comparison of model performance by ranking
the outcome. The use of statistical testing to support
the findings from cross-sectional observational data is
an important step forward in finding the evidence
required for supporting change [27].
Study Limitations
Use of a tool in the form of a questionnaire to aid
assessment of asthma can provide clinicians with confi-
dence that they will be able to identify patients with
sub-optimal control [3]. The questionnaire must be sim-
ple, brief, easy to use, patient centred, and suitable for
use in every consultation about asthma [7,28]. The Brit-
ish asthma guideline gives examples of a number of
tools which may be appropriate, one of which is the
Royal College of Physicians ‘Three Key Questions’
(RCP-3Q) [7]. The GINA guidelines [2] suggest several
alternate control assessment tools such as the Asthma
Control Test [29]; Asthma Control Questionnaire [30];
Asthma Therapy Assessment Questionnaire [31]; and
the Asthma Control Scoring System [32]. Both guide-
lines stop short of recommending any one particular
Table 5 Level of reported symptoms within each treatment step
BTS Treatment step 0
n = 5,477
1
n = 7,274
2
n = 29,629
3
n = 10,678
4
n = 11,491
5
n = 380
Symptoms 4,401
80%
6,065
83%
24,801
84%
8,754
82%
10,125
88%
357
94%
A Chi squared test for trend showed a statistically significant difference in distribution: l2 trend 146.811 df 1 p < 0.0001
20 21 21 22 19
11
26 24 28 26
27
24
34
39
34
34
43
60
0
10
20
30
40
50
60
70
0 1 2 3 4 5
%
BTS Treatment Step
Symptom Frequency according to Medication Treatment Step
1-2/Month 1-2/ Week Daily
Figure 9 Symptom frequency according to BTS medication treatment step.
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tool for use in the primary care setting. The disparity in
their ‘recommendations’ highlights the level of uncer-
tainty that still exists on the best method for use in pri-
mary care [3].
Care must therefore be taken when making conclu-
sions based on cross-sectional data from an observa-
tional study. This study was not designed to test the
RCP-3Qs but to look at how poor control was being
defined and operationalised in primary care and to test,
where possible, the strength of each assessment model
for predicting poor control of asthma. The data analysis
was informed by the literature reviews and utilised all
the control assessment sources possible for the available
data. The number of control models tested was
restricted by the structure of some of the other available
tools e.g. the ACQ or the ACT, and by the confines of
the existing data set. The ACQ and the ACT have more
complex scoring systems not easily deconstructed and
replicated for this analysis [30,33-35]. This limited the
number of control models that could be tested. How-
ever, it was clear from the literature that many research-
ers were basing their control assessment measures on
recommendations from published guidelines. It seemed
appropriate therefore to construct a model based on the
most commonly used criteria in the papers reviewed,
the GINA criteria for control [2]. The two additional
composite models of well/moderate control and total
control, based on the study by Bateman et al. [19], were
also constructed on this premise.
The simplicity of the RCP-3Qs meant that the model
created for the study was a direct reflection of the tools
properties (one yes answer being suggestive of poor
control). The Jones Morbidity Index on the other hand
was less clear cut, the tool indicating three levels of
morbidity (low, medium and high), and a decision was
made to use the medium morbidity level (1 Yes answer)
to define poor control [36]. A second model to capture
only the patients who fell into the more stringent sever-
ity classification (2 or 3 Yes answers) may have resulted
in a better performing model but the decision to use the
less stringent measure was in line with the parameters
for control in the RCP-3Q model. For both models, abil-
ity to measure control effectively may be dependent on
the question to which the one ‘Yes’ answer refers.
The available evidence indicated that single compo-
nent measures are not effective for identifying poor con-
trol [3,37]. The inclusion of two single item models in
the analysis provided the opportunity to test this against
both composite models of control measurement and
morbidity question models.
As we were looking at models that predicted control it
was necessary to include patients with both poor and
good control. The search criterion given to practices to
assist them with the procedure for identifying patients
for review was a pragmatic solution to facilitate organi-
sation of the invitation process. However, the conse-
quence of this guidance could have resulted in the over-
inclusion of patients at high risk of having poorly con-
trolled asthma, thus compromising the generalisability
of the study findings. The inclusion of patients on all
medication steps, and with a range of frequency and
type of control issue, indicates that the study cohort
transcended the range of asthma patients managed in
primary care. The number of patients who reported
Table 6 Comparison of performance of multiple regression models
Control Model Pseudo
R-squared
Akaike’s Information Criterion Area Under ROC Curve
RCP-3 Q Model 0.1803 46,933 .7924
95% CI 0.7963, 0.7885
Jones Morbidity Index 0.1352 77,811 .7407
95% CI 0.7444, 0.7370
GINA Control 0.0977 61,868 .7135
95% CI 0.7180, 0.7090
GOAL Total Control 0.0843 51,660 .7028
95% CI 0.7079, 0.6969
GOAL Well Controlled 0.0845 65,481 .6970
95% CI 0.7015, 0.6925
PEFR 0.0615 16,602 .7085
95% CI 0.7183, 0.6985
Overuse of SAB 0.0833 82,299 .6942
95% CI 0.6983, 0.6901
BTS Treatment Step 0.0677 78,223 .6711
95% CI 0.6756, 0.6665
Linear Regression R-squared AIC
RCP-3 Q Expanded Score Model 0.3258 28,616 N/A
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control issues is, in fact, comparable with those reported
by other studies [38-40].
Implications for practice
It is important for health professionals to accurately
assess the level of asthma control experienced by their
patients. Using a specific tool to aid this process not
only increases their ability to identify sub-optimal con-
trol [3], but provides a platform for improving commu-
nication [41,42]. The ACT is used widely in the
international primary care setting and has been tested
against the GINA standards [43-45] however the lack of
a recommended gold standard assessment tool for use
in primary care has meant that the RCP-3Qs remains
the most commonly used tool in the UK. Use of the
RCP-3Qs on every occasion and by every health profes-
sional who sees the patient for their asthma not only
has implications for the way control is assessed but has
potential for increasing confidence in the management
process.
This work, along with Thomas et al. [9], is a timely
addition to the small amount of available evidence sup-
porting the ability of the RCP-3Qs to assess asthma con-
trol. Health professionals are constantly asked to prove
the care they provide is effective. The original concept
of the RCP-3Qs was to develop a health outcome indi-
cator for the assessment of asthma morbidity that could
be used in both primary and secondary care. However,
the lack of validated evidence of the ‘tool’s’ ability to
accurately measure asthma control has limited its use.
This study provides additional evidence that, in the
absence of a gold standard definition of control and
assessment method, the RCP-3Q tool has the ability to
identify poor control in patients with asthma.
Conclusion
Practical guidance on the best method to monitor and
assess asthma control is required. The study underpin-
ning this work was conducted on a large number of
patients with a wide range of asthma severity and con-
trol, and from all levels of social strata across the UK.
It supports the conclusions of Thomas et al. [9] that,
along with other assessment tools such as the ACT,
the RCP-3Qs can be used with confidence in UK pri-
mary care when reviewing people with asthma. It is
quick and easy to complete and can be used with or
without a scoring system, although the latter is more
sensitive to poor control. The results may prove useful
when determining future support strategies for UK Pri-
mary Care. Until there is evidence to negate its use in
favour of another tool its use in UK primary care
should be supported.
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